Commentary

Video

Dr Rifkin on Efficacy and Safety Data From the Dreamm-7 Trial in R/R Myeloma

Author(s):

Robert M. Rifkin, MD, FACP
Conference|ASH Annual Meeting and Exposition

Robert M. Rifkin, MD, FACP, discusses the safety and efficacy of the phase 3 Dreamm-7 trial in patients with relapsed/refractory multiple myeloma.

Robert M. Rifkin, MD, FACP, medical oncologist, hematologist, Rocky Mountain Cancer Centers, discusses overall survival analysis and efficacy outcomes from the phase 3 Dreamm-7 trial (NCT04246047) in patients with relapsed/refractory multiple myeloma. Rifkin and colleagues shared this data in a presentation at the 2024 ASH Annual Meeting.

Related Videos
Timothy S. Fenske, MD, MS
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS
Charles E. Geyer, Jr., MD
Related Content
Subcutaneous Isatuximab Plus Pd in Multiple Myeloma | Image Credit: © LASZLO - stock.adobe.com
January 9th 2025

Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Multiple Myeloma | stock.adobe.com
January 6th 2025

Anito-Cel Demonstrates Safety and Early Efficacy in R/R Multiple Myeloma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Melanoma | Maris– stock.adobe.com
January 4th 2025

BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy

Urothelial Cancer | stock.adobe.com
January 3rd 2025

Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer